Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
about
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantationMycophenolate mofetil versus methotrexate for prevention of acute graft-versus-host disease in patients receiving allogeneic hematopoietic stem cell transplantationRisk factors for relapse after allogeneic transplantation in acute myeloid leukemiaPaediatric acute myeloid leukaemia with the t(7;12)(q36;p13) rearrangement: a review of the biological and clinical management aspectsAn update of current treatments for adult acute myeloid leukemiaEffects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML PatientsHow I treat pediatric acute myeloid leukemiaPost-remission therapy for acute myeloid leukemiaAllogeneic stem cell transplantation in first complete remissionProgress in acute myeloid leukemiaAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Novel therapeutic options in Acute Myeloid Leukemia'Acute myeloid leukemia: a comprehensive review and 2016 update'Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaThe EBMT activity survey: 1990-2010The indications for allogeneic stem cell transplantation in myeloid malignancies.Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission.Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study.The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative GrouComplex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.Precision oncology for acute myeloid leukemia using a knowledge bank approach.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia.Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.Transplantation immunology: solid organ and bone marrow.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Unrelated donor transplantation for acute myelogenous leukemia in first remissionFactors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Molecular therapy for acute myeloid leukaemia.Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantationNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrRecent advances in the treatment of acute myeloid leukemia.Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adultsAllogeneic hematopoietic cell transplantation: the state of the artEarly allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.
P2860
Q24194807-4F54C0B1-9114-43B2-B524-81DFD4EA0CECQ24202699-DAE4A79F-A89B-43C9-A70C-58E83D05FF82Q26771438-A1A7D79C-97EA-49BD-91BE-E207D4523BA0Q26775693-4B89A1AD-C323-41CD-A176-2160FC9ECC43Q26776396-355B302C-1E9C-4336-9A22-1EB55B4E0409Q26799602-0C4BE62B-BEB3-46E4-ADD4-4F43DE4A7E56Q26992280-EA1A0CFA-EBBA-4916-B1F3-86FE25B21F0CQ26995867-519C58E1-2448-4CF4-82A4-44B3C8B8CBE0Q26996818-A8E89148-E299-459D-81E3-624C378A4DF0Q27024006-F56C4719-B128-4EEF-8C50-43A10C8F50B3Q27851694-D20B90FE-32BC-49FD-A10F-39DF217805F4Q28069889-4756D26F-BF02-49CB-A069-3291927BD0B8Q28072539-DDA458CA-ED7B-49FE-8512-DC6E0D393224Q28075654-1A28FDCD-267E-4DA4-BADB-4A5B3EFB4C45Q28265604-365A2903-5618-4F53-857C-8D39EA80F81CQ30316611-9F839726-DAF1-43E0-B199-CE6D57FE2870Q30408294-805D55F9-8226-4B29-A337-C92A3BE6CFD5Q30884173-8A515459-3A98-4F16-B5BB-8B78A37045C6Q31052875-CA89D298-3451-495B-94D8-8AAB81152ADAQ31143348-E730F8D0-097E-4701-8899-F521FD8845A5Q33421005-338286BA-0F7F-4533-84C0-DE7E1FA740D6Q33458896-690FACD9-329B-4B77-A506-B5DAA2EC8F68Q33555627-1E1BED89-9501-4FBB-82A5-42D85124B6DAQ33611146-22DE27B2-A60C-4E94-A1A9-6CAF933B5999Q33760933-AA645891-32E8-4869-84D8-B2E3DE64BCE4Q33803804-C7F54E4B-CDE1-442C-A53B-F2542627A3D5Q33832709-D6AB2544-B472-4186-9498-2525D6E998FDQ33841417-63DDEAFA-976A-40DB-8CC6-FCB06069FF63Q33886217-ADD21D3C-B998-42A3-B765-2730ECD9FFF6Q33892358-A0693F50-6E11-4633-9577-1D783437A0F5Q33925672-E3B81038-9FBB-48B8-ADC7-36406A43425EQ34033553-6D3FED0D-17A6-4769-BFEC-FE84C6EDFD31Q34044024-82AE84A2-73E4-4592-8B4D-3E4E6273B61EQ34082437-629EB645-8769-4FDC-939B-E677E7930CE7Q34106444-97580CDC-58F0-4CD8-A1CE-57D331F9EA60Q34145155-4B7E0CE2-D4D1-42F6-9D0C-AA8DE98B6322Q34167404-3A4F5B07-FACC-4D2B-81AF-68ACC4BB9835Q34193507-91E9359F-F6C1-4136-9094-8B64C05B75FCQ34193514-5F63CE3E-48C8-45B5-88CC-FC0943A57BE2Q34200900-2DF19B6C-1CF2-4BCE-B946-2140B4C3396A
P2860
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Allogeneic stem cell transplan ...... f prospective clinical trials.
@ast
Allogeneic stem cell transplan ...... f prospective clinical trials.
@en
Allogeneic stem cell transplan ...... f prospective clinical trials.
@nl
type
label
Allogeneic stem cell transplan ...... f prospective clinical trials.
@ast
Allogeneic stem cell transplan ...... f prospective clinical trials.
@en
Allogeneic stem cell transplan ...... f prospective clinical trials.
@nl
prefLabel
Allogeneic stem cell transplan ...... f prospective clinical trials.
@ast
Allogeneic stem cell transplan ...... f prospective clinical trials.
@en
Allogeneic stem cell transplan ...... f prospective clinical trials.
@nl
P2093
P2860
P50
P356
P1476
Allogeneic stem cell transplan ...... f prospective clinical trials.
@en
P2093
Benjamin J Djulbegovic
Corey Cutler
Daniel J DeAngelo
Hisashi Sakamaki
John Koreth
Jorge Sierra
Joseph H Antin
Kenneth J Kopecky
Richard M Stone
Richard Schlenk
P2860
P304
P356
10.1001/JAMA.2009.813
P407
P577
2009-06-01T00:00:00Z